Ryan Boer, DO
Family Medicine · Great Falls, MTNPI 1598162075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 24.9% of the total. Among family medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $24.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$861
- Amgen$715
- Merck$317
- GSK$299
- AbbVie$290
- Lilly USA, LLC$272
- plus $703 from 17 others
What the payments were for
- Food & beverage$3,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $861 |
| Amgen | 25 | $715 |
| Merck | 16 | $317 |
| GSK | 14 | $299 |
| AbbVie(2 entities) | 17 | $290 |
| Lilly USA, LLC | 14 | $272 |
| Sanofi Pasteur Inc. | 5 | $97 |
| Corcept Therapeutics | 1 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $78 |
| Astellas Pharma US Inc | 3 | $67 |
| Pfizer | 3 | $49 |
| Novo Nordisk | 3 | $49 |
| Bayer | 3 | $47 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Novartis | 2 | $31 |
| Exact Sciences | 1 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,458 in reported general payments places this provider in the 95th percentile of 426 family medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $114,974 |
| EliquisApixaban | 80 | $87,404 |
| JanuviaSitagliptin Phosphate | 54 | $69,865 |
| FarxigaDapagliflozin Propanediol | 62 | $61,213 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 39 | $39,635 |
| JardianceEmpagliflozin | 23 | $25,298 |
| MyrbetriqMirabegron | 23 | $24,689 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $11,239 |
| Bydureon BciseExenatide Microspheres | 11 | $8,225 |
| Dexlansoprazole DrDexlansoprazole | 20 | $7,930 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,901 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $5,220 |
| Varenicline Tartrate | 17 | $4,468 |
| Gabapentin | 192 | $3,721 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $3,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $49 | $114,97472 claims |
| MerckJanuvia, Janumet Xr | $317 | $109,50093 claims |
| PfizerEliquis | $49 | $87,40480 claims |
| AstraZenecaFarxiga, Symbicort | $861 | $66,43373 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $24,68923 claims |
| GSKTrelegy Ellipta | $299 | $11,23912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 family medicine providers in Montana.
Other family medicine in Great Falls
- Lyle OnstadGreat Falls$5K
- Carey WelshGreat Falls$5K
- Libby LakeGreat Falls$4K
- Megan BrinkaGreat Falls$3K
- Craig TreptowGreat Falls$3K
- Joseph LeeGreat Falls$2K
- Kevin McCreaGreat Falls$2K
- Jodi Weisser ViolettGreat Falls$1K
- Venkatesh JairamGreat Falls$949
- David EngbrechtGreat Falls$786
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.